The National Hemophilia Foundation (NHF) is pleased to announce a new brochure created to give consumers a better understanding of prolonged half-life factor products recently approved by the US Food and Drug Administration for individuals with hemophilia A and B. By prolonging the time that clotting factor circulates in the blood, these products offer longer protection from bleeding episodes and require less frequent infusions. Availability of these new treatments will no doubt prompt questions from patients. NHF hopes that this brochure will both provide baseline knowledge of these novel clotting factors and foster further discussion between patients, families and their healthcare providers.
“Role of New Prolonged Half-Life Clotting Factors in Hemophilia,” which was developed independently by an NHF working group, includes a basic explanation of the differences between these newer products and traditional factor therapies, and the treatment choice implications for consumers. It also provides a description and helpful graphic representation of factor half-life. The brochure is now available through HANDI, NHF’s information service, via email: handi@hemophilia.org or via phone: 800.424.2634. Be sure to include your name, mailing address and phone number in any email requests.
